Johnson & Johnson (J&J) reported a 4.2 percent increase in its worldwide sales to $17.8 billion in the third quarter as compared to the same quarter a year ago, driven by the successful launch of new products and the strength of its core businesses, in particular the pharmaceutical segment.

In J&J's vision care business, worldwide sales increased by 8.2 percent to $739 million, driven by strong results by Acuvue contact lenses.

Pharmaceutical sales rose by 9.2 percent to $8.4 billion.

During the third quarter, J&J announced a definitive agreement to purchase Abbott Medical Optics, a wholly-owned subsidiary of Abbott Laboratories, for $4,325 million in cash.